Skip to main content
Premium Trial:

Request an Annual Quote

Number Crunch Pipe Dreams?

Premium

Pipe Dreams?

Pharmas like to dismiss genomics-cum-drug companies, saying that developing a viable pipeline requires a lot more than an altered business plan. But genomics execs argue that once their products get to market, they’ll get the recognition they deserve. GT checked out the pipelines of a sampling of companies that rely on genomics, or were genomics shops in former lives.

Oxford GlycoSciences

Genomics- and proteomics-based discovery has led to:

6 products in lead discovery

2 products in pre-clinical development

1 product in clinical development

1 product in regulatory review

 

Millennium Pharmaceuticals

Shifted from pure genomic focus to drugs early on:

8 products in Phase I

1 product in Phase II

1 product as far as Phase III

 

Human Genome Sciences

Vaunts traditional discovery with genomics spin:

4 products in pre-clinical

4 products in Phase I

1 product in Phase II

 

Vertex Pharmaceuticals

With an arsenal relying on chemogenomics, this company has:

2 products in research stage

8 products in pre-clinical

2 products in Phase I

5 products in Phase II

1 product in Phase III

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.